Outcome Capital Expands Its Medical Device and Life Science Services Practices with the Addition of Industry Veteran Peter F. Meyer, Ph.D.

“I’m thrilled to join Outcome Capital’s exceptional team; I look forward to leveraging Outcome’s unique strategy-led execution approach and my own experience as a strategic acquirer to help our clients find and prepare for an appropriate exit transaction”

An industry veteran with over 25 years of strategic investment and commercial execution experience in MedTech and the Life Sciences, Dr. Meyer brings a professional focus on leveraging industry best-practices for strategy development, market entry and growth acceleration. He has represented buy-side and sell-side interests across a wide range of clinical segments and business models, closing well over $3B in acquisition, partnership, and equity investments.

Dr. Oded Ben-Joseph, Managing Partner at Outcome Capital commented, “We have an increasing number of mid- to growth-stage companies seeking sound strategies for mergers and acquisitions, private debt and equity placement, and other strategic and corporate finance advisory services. Unique among investment banking firms, Outcome’s strategic approach to value enhancement relies on significant corporate and operational experience. Peter brings deep domain expertise across multiple disciplines and will complement Outcome’s entrepreneurial culture.”

Prior to joining Outcome Capital, Dr. Meyer was Vice President of Strategy and Corporate Development at Vicarious Surgical, an early-stage developer of soft-tissue surgical robotics. He previously served as Senior Director of Business Development for Insulet Corporation, orchestrating investments in margin and portfolio expansion for this leading manufacturer of diabetes technology. In a series of increasingly senior roles within MedTech giants Medtronic and Covidien, Dr. Meyer oversaw corporate transformational growth programs and implemented industry best-practices for strategic business optimization.

Dr. Meyer earned a Ph.D. in Biomedical Engineering from Boston University, a B.S. in Mechanical Engineering from Columbia University, and a B.S. in Math, Physics, & Chemistry from Providence College. He is a certified Design for Six Sigma Black Belt and holds over 30 patents in medical technology.

“I’m thrilled to join Outcome Capital’s exceptional team; I look forward to leveraging Outcome’s unique strategy-led execution approach and my own experience as a strategic acquirer to help our clients find and prepare for an appropriate exit transaction,” commented Dr. Meyer.

About Outcome Capital
Outcome Capital is a highly specialized life sciences and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.